• 1
    Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285: 105970.
  • 2
    Dong M, Yeh F, Tepp WH et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 5926.
  • 3
    Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxoid. Annu. Rev. Pharmacol. Toxicol. 1986; 26: 42753.
  • 4
    Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 2001; 8: 219.
  • 5
    Brin MF, Lew MF, Adler CH et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type-A resistant cervical dystonia. Neurology 1999; 53: 143148.
  • 6
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988; 39: 91922.
  • 7
    Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum A toxin as a treatment of detrusor sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J. Urol. 1996; 155: 10239.
  • 8
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. 2000; 164: 6927.
  • 9
    Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: 86872.
  • 10
    Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: 827.
  • 11
    Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 25965.
  • 12
    Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 8715.
  • 13
    Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2011; 39: 181520.
  • 14
    Mangera A, Andersson KE, Apostolidis A et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur. Urol. 2011; 60: 78495.
  • 15
    Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J. Urol. 2003; 170: 190812.
  • 16
    Kuo HC. Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003; 61: 5504.
  • 17
    Phelan MW, Franks M, Somogyi GT et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol. 2001; 165: 110710.
  • 18
    Kuo HC. Comparison of the therapeutic effects of urethral injections of 50 and 100 units of botulinum A toxin for voiding dysfunction. Tzu Chi Med. J. 2007; 19: 1348.
  • 19
    Chen YH, Kuo HC. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol. Int. 2004; 73: 15661.
  • 20
    Kuo HC. Effectiveness of treatment of voiding dysfunction after radical hysterectomy by botulinum A toxin urethral injection. Urol. Int. 2005; 75: 24751.
  • 21
    Kuo HC. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 2007; 69: 5762.
  • 22
    Lim SK, Quek PL. Intraprostatic and bladder neck injection of botulinum toxin A in treatment of males with bladder neck dyssynergia: a pilot study. Eur. Urol. 2008; 53: 6205.
  • 23
    Chen JL, Chen CY, Kuo HC. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction. J. Formos. Med. Assoc. 2009; 108: 9506.
  • 24
    Mahfouz W, Karsenty G, Corcos J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update. Can. J. Urol. 2011; 18: 578795.
  • 25
    Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am. J. Manag. Care 2000; 6: S58090.
  • 26
    Yiangou Y, Facer P, Ford A et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001; 87: 7749.
  • 27
    Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in the urothelium of neurogenic human bladders and the effect of intravesical resiniferatoxin. Urology 2005; 65: 4005.
  • 28
    Sun Y, Chai TC. Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J. Urol. 2004; 171: 44852.
  • 29
    Yoshida M, Miyamae K, Iwashida H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during ageing. Urology 2004; 63: 1723.
  • 30
    Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem. Int. 2004; 45: 98793.
  • 31
    Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol. 2005; 174: 97783.
  • 32
    Ha US, Park EY, Kim JC. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction- induced detrusor overactivity. Urology 2011; 78: 721.e16.
  • 33
    Kanai A, Wyndaele JJ, Andersson KE et al. Researching bladder afferents-determining the effects of beta(3)-adrenergic receptor agonists and botulinum toxin type-A. Neurourol. Urodyn. 2011; 30: 68491.
  • 34
    Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol. Urodyn. 2005; 24: 2316.
  • 35
    Rajkumar GN, Small DR, Mustafa AW, Conn CT. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005; 96: 84852.
  • 36
    Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J. Urol. 2005; 174: 9849.
  • 37
    Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66: 948.
  • 38
    Kuo HC. Will suburothelial injection of a small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006; 68: 9938.
  • 39
    Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am. J. Obstet. Gynecol. 2005; 192: 173540.
  • 40
    Schmid DM, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J. Urol. 2006; 176: 17785.
  • 41
    Anger JT, Weinberg A, Suttorp MJ, Litwin MS, Shekelle PG. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systemic review of the literature. J. Urol. 2010; 183: 225864.
  • 42
    Game X, Khan S, Panicker JN et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int. 2011; 107: 178692.
  • 43
    Downson C, Watkins J, Khan MS, Dasqupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur. Urol. 2012; 61: 8349.
  • 44
    Marte A, Borrelli M, Sabatino MD et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur. J. Pediatr. Surg. 2010; 20: 1537.
  • 45
    McDowell DT, Noone D, Tareen F, Waldron M, Quinn F. Urinary incontinence in children: botulinum toxin is a safe and effective treatment option. Pediatr. Surg. Int. 2012; 28: 31520.
  • 46
    Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst. Rev. 2011; (12) CD005493.
  • 47
    Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 2007; 177: 22316.
  • 48
    Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007; 100: 13026.
  • 49
    Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J. Urol. 2010; 184: 241622.
  • 50
    Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P. Efficacy and safety of low doses of onabotulinumtoxinA for the treament of refractory idiopathic overactive bladder: a multicentre, double-blind, randomized, placebo-controlled dose-ranging study. Eur. Urol. 2012; 61: 5209.
  • 51
    Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haaq-Molkenteller C, Dasqupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-ranging study in idiopathic overactive bladder. Neurouol Urodyn 2011; 30: 55602.
  • 52
    Kanagarajah P, Ayyathurai R, Caruso DJ, Gomez C, Gousse AE. Rle of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. Int. Urol. Nephrol. 2012; 44: 917.
  • 53
    Sahai A, Downon C, Khan MS, Dasqupta P, GKT Botulinum Study Group. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010; 75: 5528.
  • 54
    Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 2008; 180: 21722.
  • 55
    Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur. Urol. 2010; 58: 91926.
  • 56
    Chen YC, Kuo HC. Difficult urination does not affect the successful outcome after 100U onabotulinumtoxinA intravesical injection in patients with idiopathic detrusor overactivity. LUTS 2012; 4: 2934.
  • 57
    Makovey I, Davis T, Guralnick ML, O'Connor RC. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol. Urodyn. 2011; 30: 153840.
  • 58
    Kuo HC. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxinA injection for idiopathic detrusor overactivity. Neurourol. Urodyn. 2011; 30: 1497502.
  • 59
    Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol. Urodyn. 2011; 30: 12428.
  • 60
    Ke Q-S, Chen Y-C, Kuo H-C. Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor overactivity? Tzu Chi Med. J. 2012;
  • 61
    Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J. Urol. 2007; 178: 135963.
  • 62
    Manecksha RP, Cullen IM, Ahmad S et al. Prospective randomized controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur. Urol. 2012; 61: 92835.
  • 63
    Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J. Urol. 2007; 177: 10114.
  • 64
    Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury types of detrusor sphincter dyssynergia. Spinal Cord 2011; 49: 65964.
  • 65
    Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology 2000; 56: 5658.
  • 66
    Ahmed HU, Shergill IS, Arya M, Shah PJ. Management of detrusor-external sphincter dyssynergia. Nat. Clin. Pract. Urol. 2006; 3: 36880.
  • 67
    Schulte-Baukloh H, Schobert J, Stolze T, Sturzebecher B, Weiss C, Knispel HH. Efficacy of botulinum-A bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol. Urodyn. 2006; 25: 1105.
  • 68
    Conte A, Giannantoni A, Proietti S et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overacivity. Eur. J. Neurol. 2012; 19: 72532.
  • 69
    Munoz A, Somogyi GT, Boone TB, Smith CP. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury. Neurourol. Urodyn. 2011; 30: 137681.
  • 70
    Reitz A, Stohrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur. Urol. 2004; 45: 5105.
  • 71
    Schurch B, de Seze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 2005; 174: 196200.
  • 72
    Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur. Urol. 2005; 47: 6539.
  • 73
    Herschorn S, Gajewski J, Ethans K et al. Efficacy of botulinum txin A injection for neurogenic detrusor overactivity and urnary incontinence: a randomized, double-blind trial. J. Urol. 2011; 185: 222935.
  • 74
    Khan S, Game X, Kalsi V et al. Long-term effect on quality of life of repeated detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J. Urol. 2011; 185: 13449.
  • 75
    Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J. Urol. 2010; 184: 10116.
  • 76
    Kulaksizoglu H, Parman Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson's disease. Parkinsonism Relat. Disord. 2010; 16: 5314.
  • 77
    Giannantoni A, Conte A, Proietti S et al. Botulinum toxin type A in atients with Parkinson's disease and refractory overactive bladder. J. Urol. 2011; 186: 9604.
  • 78
    Cruz F, Herschorn S, Aliotta P et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur. Urol. 2011; 60: 74250.
  • 79
    Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder- to include or excude the trigone? A prospective, andomized, controlled trial. J. Urol. 2010; 184: 24238.
  • 80
    Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 2000; 55: 4904.
  • 81
    Schulte-Baukloh H, Weiss C, Stolze T et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur. Urol. 2005; 48: 98490.
  • 82
    Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006; 67: 2326.
  • 83
    Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesion and detrusor sphincter dyssynergia who received detrusor botulinumt toxin A injection. Urology 2008; 72: 105660.
  • 84
    Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology 2001; 57: 26.
  • 85
    Nickel JC, Barkin J, Forrest J et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65: 6548.
  • 86
    Sant GR, Propert KJ, Hanno PM et al. A pilot clinical trial of oral pentosan polysulphate and oral hydroxyzine in patients with interstitial cystitis. J. Urol. 2003; 170: 8105.
  • 87
    Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J. Urol. 1989; 141: 8468.
  • 88
    Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J. Urol. 2005; 171: 213841.
  • 89
    Bouchelouche K, Nordling J. Recent developments in the management of interstitial cystitis. Curr. Opin. Urol. 2003; 13: 30913.
  • 90
    Teichman JM, Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can. J. Urol. 2007; 14: 3599607.
  • 91
    Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol. 1997; 79: 5727.
  • 92
    Okragly AJ, Niles AL, Saban R et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J. Urol. 1999; 161: 43841.
  • 93
    Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007; 69: 3440.
  • 94
    Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome. Cell. Signal. 2008; 20: 21749.
  • 95
    Southgate J, Varley CL, Garthwaite MA et al. Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int. 2007; 99: 150616.
  • 96
    Brady CM, Apostolidis AN, Harper M et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. 2004; 93: 7706.
  • 97
    Cockayne DA, Hamilton SG, Zhu QM et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000; 407: 10115.
  • 98
    Beltinger J, McKaig BC, Makh S, Stack WA, Hawkey CJ, Mahida YR. Human colonic sub-epithelial myofibroblasts modulate tranepithelial resistance and secretory response. Am. J. Physiol. 1999; 277: C2719.
  • 99
    Cayan S, Coskun B, Bozlu M, Acar D, Akbay E, Ulusoy E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol. Res. 2003; 30: 399404.
  • 100
    Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol. 2006; 175: 113842.
  • 101
    Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats. J. Urol. 2004; 172: 152932.
  • 102
    Giannantoni A, Di Stasi SM, Nardicchi V et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J. Urol. 2006; 175: 23414.
  • 103
    Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol. 2009; 56: 15966.
  • 104
    Cui M, Aoki KR. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000; 20: 4148.
  • 105
    Seki S, Sasaki K, Fraser MO et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J. Urol. 2002; 168: 226974.
  • 106
    Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat. Clin. Pract. Urol. 2006; 3: 10110.
  • 107
    Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol. Int. 2005; 75: 1704.
  • 108
    Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur. Urol. 2006; 49: 7049.
  • 109
    Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol. Urodyn. 2011; 30: 936.
  • 110
    Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104: 65761.
  • 111
    El-Bahnasy AE, Farahat YA, El-Bendary M et al. A randomized controlled trial of bacillus Calmette-Guerin and botulinum toxin-A for the treatment of refractory interstitial cystitis. UroToday Int. J. 2009; doi:10.3834/uij.1944-5784.2008.12.06.
  • 112
    Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow up. J. Urol. 2008; 179: 10314.
  • 113
    Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr. Drug Deliv. 2010; 7: 14.
  • 114
    Giannantoni A, Cagini R, Del Zingaro M et al. Botulinum a toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and quality of life. Curr. Drug Deliv. 2010; 7: 4426.
  • 115
    Pinto R, Lopes T, Frias B et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 2010; 58: 3605.
  • 116
    Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon 2007; 5: 3313.
  • 117
    Kuo YC, Kuo HC. Effect of repeated intravesical botulinum toxin A injections on treatment of refractory interstitial cystitis/painful bladder syndrome-preliminary results. 2011; ICS Abstract.
  • 118
    Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Groups. N. Engl. J. Med. 1996; 335: 5339.
  • 119
    Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled multicenter study. PROWESS Study Group. Urology 1998; 51: 67786.
  • 120
    AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. 2003; 170: 53047.
  • 121
    McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, fnateride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 238798.
  • 122
    Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol. Ther. 2002; 94: 93112.
  • 123
    Higgins JR, Gosling JA. Studies of the structure and intrinsic innervation of the normal human prostate. Prostate 1989; 2: 516.
  • 124
    Gkonos PJ, Krongrad A, Roos BA. Neuroendocrine peptides in the prostate. Urol. Res. 1995; 23: 817.
  • 125
    Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J. Urol. 2004; 171: 212837.
  • 126
    Smith CP, Franks ME, McNeil BK et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J. Urol. 2003; 169: 1896900.
  • 127
    Kuo HC. Prostate botulinum A toxin injection- an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 6704.
  • 128
    Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. BOTOX-induced prostatic involution. Prostate 1998; 37: 4450.
  • 129
    Chuang YC, Huang CC, Kang HY et al. Novel action of botulinum toxin on the stroma and epithelial components of the prostate gland. J. Urol. 2006; 175: 115863.
  • 130
    Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur. Urol. 2007; 52: 5829.
  • 131
    Silva J, Pinto R, Carvallho T et al. Mechanisms of prostate atrophy after landular botulinum neurotoxin type a injection: an experimental study in rat. Eur. Urol. 2009; 56: 13440.
  • 132
    Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006; 98: 10337.
  • 133
    Silva J, Silva C, Saraiva L et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur. Urol. 2008; 53: 1539.
  • 134
    Silva J, Pinto R, Carvalho T et al. Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol. 2009; 9: 9.
  • 135
    Risinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botlinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009; 73: 904.
  • 136
    Costa P, Robert M, Sarrazin B, Mottet N, Navratil H. Quantitative topographic distribution of epithelial and mesenchymal components in benign prostatic hyperplasia. Eur. Urol. 1993; 24: 1203.
  • 137
    Matsuda T, Fujime M, Suda K. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia. Anal. Quant. Cytol. Histol. 2006; 28: 1214.
  • 138
    Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand. J. Urol. Nephrol. 2009; 43: 20611.
  • 139
    Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br. J. Urol. 1998; 81: 2933.
  • 140
    Kuo HC. Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. Urology 2007; 70: 2726.
  • 141
    Chen JL, Kuo HC. Implications of prostatic volume measurements on the degree of bladder outlet obstruction in men with benign prostatic hyperplasia and lower urinary tract symptoms. J Taiwan Urol Assoc 2006; 17: 417.